United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 43,025 shares of the firm’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $111.11, for a total transaction of $4,780,507.75. Following the transaction, the chief executive officer now directly owns 21,652 shares in the company, valued at $2,405,753.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
NASDAQ UTHR opened at $110.26 on Friday. United Therapeutics Co. has a 52-week low of $106.30 and a 52-week high of $152.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 3.01. The stock has a market cap of $4,767.64, a P/E ratio of 10.05 and a beta of 1.34.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.59 by $0.30. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The business had revenue of $464.70 million during the quarter, compared to the consensus estimate of $420.55 million. During the same quarter last year, the company posted $4.12 earnings per share. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. equities research analysts anticipate that United Therapeutics Co. will post 12.46 EPS for the current year.
A number of research analysts recently weighed in on UTHR shares. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. ValuEngine lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price target on the stock in a research report on Monday, January 15th. Credit Suisse Group raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $115.00 price target on the stock in a research report on Tuesday, April 3rd. Finally, Oppenheimer raised their price target on shares of United Therapeutics to $180.00 and gave the company an “outperform” rating in a research report on Friday, January 5th. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company’s stock. United Therapeutics has a consensus rating of “Hold” and an average target price of $135.20.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Xact Kapitalforvaltning AB increased its holdings in United Therapeutics by 3.8% during the fourth quarter. Xact Kapitalforvaltning AB now owns 11,474 shares of the biotechnology company’s stock worth $1,698,000 after buying an additional 424 shares during the last quarter. American International Group Inc. increased its stake in shares of United Therapeutics by 0.6% in the fourth quarter. American International Group Inc. now owns 91,580 shares of the biotechnology company’s stock worth $13,549,000 after purchasing an additional 524 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in shares of United Therapeutics in the fourth quarter worth about $1,812,000. California Public Employees Retirement System increased its stake in shares of United Therapeutics by 1.5% in the third quarter. California Public Employees Retirement System now owns 133,793 shares of the biotechnology company’s stock worth $15,679,000 after purchasing an additional 1,993 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of United Therapeutics by 3.5% in the third quarter. KBC Group NV now owns 22,974 shares of the biotechnology company’s stock worth $2,692,000 after purchasing an additional 783 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “Martine A. Rothblatt Sells 43,025 Shares of United Therapeutics Co. (UTHR) Stock” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/insider-selling-united-therapeutics-co-uthr-ceo-sells-43025-shares-of-stock.html.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.